Quince Therapeutics (QNCX) risk factors, FY2024 10-K

Risks Relating to Our Business

1. 01We are substantially dependent on the success of our lead drug candidate, eDSP
2. 02We have no drug candidates approved for commercial sale, we have never generated any revenue from sales, and we may never be profitable
3. 03We expect to explore partnership and licensing opportunities to support the future development of eDSP and other drug candidates. We may also encounter other unforeseen expenses, difficulties, complications, delays and other known and unknown challenges as we pursue our current strategic direction
4. 04If we are unable to continue as a going concern, we may have to cease operations and liquidate our assets. We may receive less than the value at which those assets are carried on our financial statements, and investors may lose all or a part of their investment
5. 05If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any drug candidates we may develop and for which we obtain approval, we may not be successful in commercializing those drug candidates if and when they are approved
6. 06We may encounter difficulties in managing our growth and expanding our operations successfully
7. 07We may be exposed to a variety of international risks that could materially adversely affect our business
8. 08Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations
9. 09We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants, and the loss of such persons could negatively impact the operations of the company
10. 10Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business

Risks Related to the Development of Our Drug Candidates

1. 11The Phase 3 NEAT clinical trial of eDSP for A-T is being conducted under a protocol negotiated with FDA by EryDel and our execution of the trial may be slow, may not be successful, and may not result in NDA approval, with adverse results for our business and share price
2. 12We will incur additional costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates
3. 13Our drug candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential
4. 14Clinical trials of our drug candidates may not uncover all possible AEs that patients may experience
5. 15If we are not able to successfully demonstrate a favorable differentiation between eDSP and currently available corticosteroids, our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired
6. 16Interim, top-line and preliminary data from our future clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
7. 17be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies
8. 18Even if we obtain regulatory approval for a drug candidate, it will remain subject to extensive ongoing regulatory review and requirements
9. 19A Fast Track designation by the FDA, such as the Fast Track designations received for eDSP, does not guarantee marketing approval and may not lead to a faster development, regulatory review or approval process
10. 20We may be unable to obtain and retain orphan drug designations for some of our drug candidates or to maintain the benefits associated with orphan drug designation status, including market exclusivity, which may cause our revenue, if any, to be reduced

Risks Relating to Our Financial Position

1. 21We are a clinical stage biotechnology company and have a limited history operating a newly acquired business, which may make it difficult to evaluate the prospects for our future viability
2. 22The terms of the EIB Loan place restrictions on our operating and financial flexibility
3. 23Our financial results have been in the past and may in the future be adversely affected by impairment charges from the recording of goodwill and intangible assets
4. 24Unstable market and global economic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions, may have adverse consequences on our business, financial condition and stock price
5. 25Our failure to maintain certain tax benefits applicable to Italian biotechnology companies may adversely affect our results of operations, our cash flows and our financial condition

Risks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters

1. 26We cannot be certain that the FDA or foreign regulatory authorities will permit us to proceed with any current or future proposed clinical trial designs. Our drug candidates may not receive regulatory approval, and without regulatory approval we will not be able to market our drug candidates
2. 27We currently have no drug candidates approved for sale and we cannot guarantee that we will ever have marketable drug candidates. Our ability to generate revenue related to sales, if ever, will depend on the successful development and regulatory approval of our drug candidates
3. 28Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations
4. 29The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act(collectively, the “PPACA”) substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry
5. 30other healthcare funding, which may adversely affect customer demand and affordability for our drug candidates and, accordingly, the results of our financial operations
6. 31manufactured in accordance with the guidelines on GMP and in a GMP licensed facility, which can be subject to GMP inspections
7. 32Our ability to successfully commercialize any drugs that we develop depends in part on the extent to which coverage and adequate reimbursement are available from government health administration authorities, private health insurers, and other organizations
8. 33the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status
9. 34If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected
10. 35If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
11. 36Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws

Risks Related to the Production and Manufacturing of our Drug Candidates and Future Products

1. 37Our production capacity could prove insufficient for our needs
2. 38We are dependent on third parties for the supply of various materials that are necessary to produce our drug candidates for clinical trials
3. 39Our manufacturing facilities are subject to significant government regulations and approvals. If we or our third-party manufacturers fail to comply with these regulations or maintain these approvals, our business will be materially harmed
4. 40Our production costs may be higher than we currently estimate
5. 41The manufacture of our products requires strict adherence to regulatory requirements governing medical devices and if we or our suppliers encounter problems our business could suffer
6. 42Any failure to comply with any of these obligations may impact our activities in the EEA, the renewal of our existing CE Certificates of Conformity and future conformity assessment activities
7. 43If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates, if approved
8. 44The United Kingdom’s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our common stock
9. 45end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP
10. 46Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities
11. 47Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize potential future drug candidates

Risks Relating to Our Intellectual Property

1. 48Should any of these events occur, they would significantly harm our business, results of operations and prospects
2. 49Our success will depend in part on our ability to operate without infringing the intellectual property rights of third parties. We cannot guarantee that our drug candidates, or manufacture or use of our drug candidates, will not infringe third-party patents
3. 50proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of drug candidates or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform
4. 51If we are sued for patent infringement, we would need to demonstrate that our drug candidates or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity or unenforceability is difficult
5. 52We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
6. 53Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
7. 54We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and drug candidate could be significantly diminished
8. 55In the future, we may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated
9. 56Intellectual property rights do not necessarily address all potential threats to our competitive advantage
10. 57Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
11. 58We may not be able to protect our intellectual property rights throughout the world
12. 59Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates
13. 60We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
14. 61Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time, and if we do not obtain patent term extension for our drug candidates, our business may be materially harmed
15. 62If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
16. 63We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable
17. 64We may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses

Risks Relating to Owning Our Common Stock

1. 65The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment
2. 66We may be subject to securities class action and stockholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management’s time and attention from our business and adversely impact our business, results of operations and financial condition
3. 67Future sales of our common stock in the public market could cause our share price to fall
4. 68Moreover, we have also registered under the Securities Act shares of common stock that we may issue under our equity compensation plans
5. 69We have in the past and may in the future fail to meet the requirements for continued listing on Nasdaq. If we fail to maintain compliance with the minimum listing requirements, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock
6. 70We have never paid dividends on our common stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases
7. 71Our stockholders may realize little or no value from the divestiture of our legacy assets, and as a result our stock price may decline, we could be subject to litigation, and our business may be adversely affected
8. 72Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock
9. 73Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
10. 74Our ability to utilize our federal net operating loss and tax credit carryforwards may be limited
11. 75of taxable income for tax years beginning January 1, 2018. NOLs generated in Italy are subject to Italian tax laws and deductibility of such Italian NOLs may be limited to 80% of taxable income